Responses
Late-breaking abstracts
Clinical trials completed
795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Compose a Response to This Article
Other responses
No responses have been published for this article.